| Name | Pinometostat |
| Description | Pinometostat (EPZ-5676) is a potent DOT1L histone methyltransferase inhibitor (Ki=80 pM). Pinometostat has antitumor activity and can be used in experiments to study a variety of leukemia treatments. |
| Cell Research | EPZ-5676 is dissolved in DMSO. To analyse inhibition of histone methylation in MV4-11 cells following EPZ-5676 treatment, extracted histones (400 ng) are fractionated on a 10-20% Tris HCl gels with Tris-Glycine SDS running buffer under denaturing conditions and transferred to nitrocellulose filters. Filters are cut into strips and incubated for 1 hour in blocking buffer at room temperature (RT) and then incubated overnight at 4°C in blocking buffer. Filters are washed 3 times for 5 minutes with wash buffer (Phosphate buffered saline (PBS) including 0.01% Tween 20 (PBST)) and incubated with infrared tagged secondary antibody at RT for 1 hour. Filters are washed in PBST and reprobed for 1 hour at RT with the appropriate total histone antibody control (mouse anti-histone H3 (1:20,000), CST 3638, or mouse anti-histone H4 (1:10,000), CST 2935). Filters are washed again in PBST and incubated with infrared tagged secondary antibody (IRDye 800Cw donkey-anti-mouse IgG (1:20,000), Li-Cor 926-32212) at RT for 1 hour. After a final ish in PBST, filters are scanned using the Odyssey infared imager (Li-cor). To analyse inhibition of H3K79 methylation in peripheral blood mononuclear cells (PBMCs) from rats dosed with EPZ-5676, 20 μL of PBMC whole cell lysate is fractionated on denaturing gels and analysed by immunoblotting with antibodies to H3K79me2 or total H3. Signal intensities specific for the H3K79me2 antibody and total histone H3 control antibody are quantified using Odyssey software. The H3K79me2 signal intensity is normalized by dividing it by the total histone H3 control signal intensity in the same lane. |
| In vitro | METHODS: MLL-r and non-MLL-r AML cells were treated with Pinometostat (0.1-10 µM) for 4-16 days and cell proliferation was detected by flow cytometry.
RESULTS: The MV4-11, MOLM-13 and NOMO-1 cell lines carrying MLL-AF4 or MLL-AF9 fusions showed a dramatic decrease in cell numbers after 8 days of treatment, with IC50 values below 1 µM. In contrast, the proliferation of U-937 or HL-60 cells, which are all lacking in MLL-r, was not affected by Pinometostat. Surprisingly, DOT1L inhibition had no effect on MLL-AF9-positive THP-1 cells, whereas it significantly reduced the proliferation of the non-MLL-r OCI-AML3 cell line. [1]
METHODS: Human leukemia cells MV4-11 were treated with Pinometostat (0.06-1000 nM) for 4 days and target protein expression levels were detected by Western Blot.
RESULTS: A concentration-dependent decrease in overall cellular methylated H3K79 levels was observed in MV4-11 expressing MLL-AF4 at increasing concentrations of Pinometostat. [2] |
| In vivo | METHODS: To detect anti-tumor activity in vivo, Pinometostat (50 mg/kg, 2% DMSO+30% PEG 300+5% Tween80+63% PBS) was injected intraperitoneally into NSG mice bearing MDA-MB-468 tumors every two days and administered six times.
RESULTS: Pinometostat significantly reduced tumor volume and primary tumor metastasis within 10 weeks. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 85 mg/mL (151.1 mM)
DMSO : 60 mg/mL (106.63 mM)
|
| Keywords | Pinometostat | EPZ5676 | Inhibitor | inhibit | Histone Methyltransferase | EPZ 5676 |
| Inhibitors Related | BIX-01294 trihydrochloride | Tazemetostat | Piribedil | XY1 | UNC 0631 | GSK126 | MAK683 | EZM 2302 | EPZ015666 | AMI-1 free acid | MS37452 | MRTX-1719 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
